Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis. However, its prognostic evaluation is still an urgent problem. The objectives of this present study were to investigate oncofetal antigen glypican-3 (GPC-3) expression in HCC and their match para-cancerous tissues by the array technology with immunohistochemistry and estimate its value as a novel prognostic marker for HCC. The incidence of GPC-3 expression was 95.7 % in the cancerous tissues with significantly higher (χ2 = 33.824, P < 0.001) than that in the para-cancerous tissues (52.2 %). Abnormal expression of GPC-3 in HCC tissues was markedly related to poor or moderate differentiation (P < 0.001), hepatitis B virus (HBV) infection (P = 0.004), periportal cancer embolus (P = 0.043), and tumor-node- metastasis staging (P = 0.038). According to the univariate and multivariate analysis, the overall survival of HCC patients with high GPC-3 level was significantly worse than those with low or without GPC-3 expression (P < 0.001), suggesting that abnormal GPC-3 expression should be an independent prognostic factor for HBV-related HCC patient's survival.
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.|Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, China.
Li
L
Wang
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
Liuhong
L
Pan
Department of Immunology, Medical School of Nantong University, Nantong 226001, China.
Min
M
Yao
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
Yin
Y
Cai
Department of Diagnostics, Affiliated Hospital of Nantong University, Nantong 226001, China.
Zhizhen
Z
Dong
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
Dengfu
D
Yao
D000951:Antigens, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000378:metabolism / Q000821:virology*; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D053673:Glypicans / Q000378:metabolism*; D006509:Hepatitis B / Q000150:complications; D006515:Hepatitis B virus; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000821:virology*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D046888:Tissue Array Analysis
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C105937:GPC3 protein, human; D053673:Glypicans; C031192:oncofetal antigens
glypican-3; hepatocellular carcinoma; immunohistochemistry; prognosis; tissue microarrays